预约演示

更新于：2025-05-07

Chronic peptic ulcer

慢性消化性溃疡

更新于：2025-05-07

基本信息

别名

Chronic peptic ulcer、Chronic peptic ulcer (disorder)、chronic peptic ulcer

+ [4]

简介-

关联

项与慢性消化性溃疡相关的药物

Pantoprazole Sodium Hydrate

泮托拉唑钠

靶点

Proton pump

作用机制

质子泵抑制剂

在研机构

Takeda Pharmaceuticals Australia Pty Ltd. [+9]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研适应症

糜烂性食管炎 [+8]

非在研适应症

慢性消化性溃疡 [+6]

最高研发阶段批准上市

首次获批国家/地区

德国

首次获批日期1994-01-01

项与慢性消化性溃疡相关的临床试验

IRCT20091114002709N63

/ RecruitingN/A

The effect of beginning time of oral feeding on the length of hospitalization, risk of rebleeding and nutritional status of patients with upper gastrointestinal bleeding caused by peptic ulcers and erosive diseases

开始日期2023-08-13

申办/合作机构

Iran University of Medical Sciences & Health Services

CTR20222536

/ CompletedN/A

奥美拉唑镁肠溶片人体生物等效性研究（空腹）

主要目的：本试验旨在研究单次空腹口服重庆莱美药业股份有限公司研制、生产的奥美拉唑镁肠溶片（20 mg）的药代动力学特征；以AstraZeneca AB生产的奥美拉唑镁肠溶片（洛赛克MUPS®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要目的：观察受试制剂奥美拉唑镁肠溶片和参比制剂奥美拉唑镁肠溶片（洛赛克MUPS®）在健康受试者中的安全性。

开始日期2022-10-08

申办/合作机构

重庆莱美药业股份有限公司

CTR20221107

/ CompletedN/A

奥美拉唑镁肠溶片人体生物等效性研究（餐后试验）

主要目的：本试验旨在研究单次餐后口服重庆莱美药业股份有限公司研制、生产的奥美拉唑镁肠溶片（20 mg）的药代动力学特征；以AstraZeneca AB生产的奥美拉唑镁肠溶片（洛赛克MUPS®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要目的：观察受试制剂奥美拉唑镁肠溶片和参比制剂奥美拉唑镁肠溶片（洛赛克MUPS®）在健康受试者中的安全性。

开始日期2022-05-27

申办/合作机构

重庆莱美药业股份有限公司

100 项与慢性消化性溃疡相关的临床结果

登录后查看更多信息

100 项与慢性消化性溃疡相关的转化医学

登录后查看更多信息

0 项与慢性消化性溃疡相关的专利（医药）

登录后查看更多信息

481

项与慢性消化性溃疡相关的文献（医药）

2025-08-01·Tissue and Cell

Apigenin improves chronic gastric ulcer in rats: The implication of COX-1/2 and 5-LOX signaling pathways

Article

作者: Nasr El-Din, Wael Amin ; Abdel Fattah, Islam Omar

Peptic ulcer is a prevalent gastrointestinal illness. The aim is to investigate the possible implication of cyclooxygenase (COX)-1/2 and 5-lipoxygenase (5-LOX) signaling pathways in apigenin therapeutic effect on acetic acid-induced chronic gastric ulcer maintained with indomethacin. Rats were divided into 5 groups (n = 10): control, ulcer, omeprazole+ulcer, apigenin+ulcer, and apigenin only groups. Evaluations were for serum oxidative stress markers, gastric acidity, histopathology, immunohistochemistry, and scanning electron microscope (SEM). The ulcer group demonstrated body weight loss, increase in gastric acidity, decline in superoxide dismutase (SOD) and catalase (CAT) antioxidant activity, increase in malondialdehyde (MDA) level, decrease in COX-1 immuno-expression, and increase in COX-2 and 5-LOX immuno-expressions. Furthermore, histopathology revealed mucosal sloughing, and parietal cell degeneration, in addition to completely degenerated mucosa. These parameters were modulated in apigenin-treated group compared to ulcer one, via improved weight gain (37.11 vs. 21.23 g) (omeprazole = 30.95), increased gastric pH (5.82 vs. 3.98) (omeprazole = 4.63), elevated SOD and CAT levels (98.14 vs. 30.31, and 500.19 vs. 132.11 U/ml) (omeprazole = 70.44 and 362.42), decreased MDA levels (3.07 vs. 28.11 ng/ml) (omeprazole = 5.51), decreased ulcer index (0.31 vs. 7.19) (omeprazole = 2.63), increased parietal cell count (625.73 vs. 334.51 cell/mm) (omeprazole = 604.69), increased COX-1 immunostain percentage (25.28 vs. 10.92) (omeprazole = 17.46), lowered COX-2 and 5-LOX immunostain percentages (10.12 vs. 42.95, and 18.32 vs. 43.62) (omeprazole = 17.02 and 23.83). In conclusion, apigenin mitigates chronic gastric ulcer parameters via involvement of COX-1/2 and 5-LOX signaling pathways, having the upper hand over omeprazole.

2024-02-01·BMJ Case Reports

Choledocho-gastric fistula due to chronic peptic ulcer with gastric outlet obstruction and pneumobilia

Article

作者: Ajmal, Imran Tariq ; Rino, Roshan V ; Anand, Priyanka ; Muralidhar, Venkiteswaran

2024-01-01·Stem Cells International

Mesenchymal Stem Cells Accelerate Recovery of Acetic Acid‐Induced Chronic Gastric Ulcer by Regulating Ekt/Akt/TRIM29 Axis

Article

作者: Fan, Zhibin ; Sui, Jianliang ; Jia, Ruikang ; Zhao, Feiyue ; Wang, Menglei ; Liu, Qichao ; Liu, Huiyun

Chronic gastric ulcer (CGU), a prevalent digestive disease, has a high incidence and is seriously harmful to human health. Mesenchymal stem cells (MSCs) have been proven to have beneficial therapeutic effects in many human diseases. Here, a CGU model induced by acetic acid in mice was used to evaluate the repair effects and potential mechanism of human umbilical cord‐derived MSCs (hUC‐MSCs) and hUC‐MSCs derived conditioned medium (hUC‐MSC‐CM). We found that hUC‐MSCs and hUC‐MSC‐CM treatment significantly repaired morphological characteristics of CGU, improved proliferation and decreased apoptosis of gastric cells, and promoted the generation of new blood vessels in granulation tissues. In addition, we could detect the homing of MSCs in gastric tissue, and MSCs may differentiate into Lgr5‐positive cells. As well as this, in vitro experiments showed that hUC‐MSC‐CM could promote cell proliferation, stimulate cell cycle progression, and reduce the incidence of apoptosis. The transcriptome of cells and the iTRAQ proteome of gastric tissues suggest that MSCs may play a therapeutic role by increasing the expression of TRIM29. Additionally, it was found that knocking down TRIM29 significantly decreased the ameliorative effects of hUC‐MSC‐CM on cell apoptosis. As a result of further molecular experiments, it was found that TRIM29 is capable of phosphorylating Erk/Akt in specific cell type. As a whole, it appears that hUC‐MSCs can be an effective therapeutic approach for promoting gastric ulcer healing and may exert therapeutic effects in the form of paracrine and differentiation into gastric cells.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。